{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "House Republicans said today that they were drafting legislation to slow the growth in Medicare payments to hospitals and had discussed the idea of charging elderly people a modest co-payment for the use of home health care services. Home care is one of the few services for which no co-payment is now charged.", "headline": {"main": "House G.O.P. Seeking Ways to Slow Growth of Hospital Outlays Under Medicare"}, "abstract": "House Republicans are drafting bill to slow growth in Medicare payments to hospitals; say they are discussing idea of charging elderly people modest co-payment for use of home health care services, one of few services for which co-payment is not charged; centerpiece of bill is proposal to add prescription drug benefits to Medicare; as corollary, House Republicans plan to alter formulas for paying hospitals, doctors, nursing homes, home health agencies and health maintenance organizations, all of which are lobbying for more money; White House officials insist that changes must not produce net increase in Medicare spending beyond what is envisioned under existing law; many lawmakers say top priority is to increase Medicare payments to doctors, some of whom are refusing to take new Medicare patients; doctors' Medicare payments were cut by 5.4 percent this year under law that will further reduce fees paid for physician service in each of next three years, for total decreases of 17 percent by 2005 (M)", "print_page": "13", "word_count": 882, "_id": "4fd235898eb7c8105d7c6f00", "snippet": "House Republicans said today that they were drafting legislation to slow the growth in Medicare payments to hospitals and had discussed the idea of charging elderly people a modest co-payment for the use of home health care services.    Home care is...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/04/27/us/house-gop-seeking-ways-to-slow-growth-of-hospital-outlays-under-medicare.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "HEALTH MAINTENANCE ORGANIZATIONS AND MANAGED CARE"}, {"name": "subject", "value": "HOME HEALTH CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "HOSPITALS"}, {"name": "subject", "value": "NURSING HOMES"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2002-04-27T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "For the first time in the history of the Food and Drug Administration, an advisory panel has recommended that a banned drug be put back on the market. The panel voted 16 to 2 to allow the return of the drug Lotronex, but with significant restrictions to protect patients from adverse effects. The F.D.A. usually follows the recommendations of its advisory panels. The details of the restrictions have yet to be worked out between the drug agency and the maker of Lotronex, GlaxoSmithKline. That process could take months, and it is likely to be at least six months before Lotronex becomes available again if the F.D.A. decides to go along with the panel's decision.", "headline": {"main": "Panel Advises Lifting Ban On Drug for Bowel Ailment"}, "abstract": "Food and Drug Administration advisory panel votes to allow drug Lotronex to be put back on market, but with significant restrictions to protect patients from adverse affects; drug, manufactured by GlaxoSmithKline, is used to treat chronic diarrhea caused by irritable bowel syndrome (M)", "print_page": "18", "word_count": 918, "_id": "4fd268b78eb7c8105d81ec6e", "snippet": "For the first time in the history of the Food and Drug Administration, an advisory panel has recommended that a banned drug be put back on the market.     The panel voted 16 to 2 to allow the return of the drug Lotronex, but with significant...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/04/24/us/panel-advises-lifting-ban-on-drug-for-bowel-ailment.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "GLAXOSMITHKLINE"}, {"name": "subject", "value": "DIARRHEA"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "LOTRONEX (DRUG)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "IRRITABLE BOWEL SYNDROME"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Denise", "lastname": "GRADY"}], "original": "By DENISE GRADY"}, "document_type": "article", "pub_date": "2002-04-24T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 2, "offset": 0, "time": 27}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}